EP1168924A4 - DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL - Google Patents

DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL

Info

Publication number
EP1168924A4
EP1168924A4 EP00921528A EP00921528A EP1168924A4 EP 1168924 A4 EP1168924 A4 EP 1168924A4 EP 00921528 A EP00921528 A EP 00921528A EP 00921528 A EP00921528 A EP 00921528A EP 1168924 A4 EP1168924 A4 EP 1168924A4
Authority
EP
European Patent Office
Prior art keywords
cells
dendritic
antigen
specific
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00921528A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1168924A1 (en
Inventor
Louis D Falo Jr
Walter Storkus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of EP1168924A1 publication Critical patent/EP1168924A1/en
Publication of EP1168924A4 publication Critical patent/EP1168924A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP00921528A 1999-03-31 2000-03-30 DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL Withdrawn EP1168924A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28267999A 1999-03-31 1999-03-31
US282679 1999-03-31
PCT/US2000/008472 WO2000057705A1 (en) 1999-03-31 2000-03-30 In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens

Publications (2)

Publication Number Publication Date
EP1168924A1 EP1168924A1 (en) 2002-01-09
EP1168924A4 true EP1168924A4 (en) 2002-09-04

Family

ID=23082644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00921528A Withdrawn EP1168924A4 (en) 1999-03-31 2000-03-30 DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL

Country Status (6)

Country Link
EP (1) EP1168924A4 (enExample)
JP (1) JP2002539805A (enExample)
CN (1) CN1353575A (enExample)
AU (1) AU4183100A (enExample)
CA (1) CA2367590A1 (enExample)
WO (1) WO2000057705A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
DE69839215T2 (de) 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride
WO2001029193A2 (de) * 1999-10-22 2001-04-26 Peter Leskovar Zellkonstrukte, die für die immuntherapie geeignet sind, deren herstellung und verwendung
AU3823601A (en) * 2000-02-11 2001-08-20 Dana Farber Cancer Inst Inc Cytotoxic t lymphocytes activated by dendritic cell hybrids
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
DE10164819A1 (de) 2001-11-20 2005-05-19 Deml, Ludwig, Dr. Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen
PT2511301T (pt) 2006-08-04 2018-03-08 Medimmune Ltd Anticorpos humanos para erbb2
DE102010037622B4 (de) * 2010-09-17 2012-07-12 Lophius Biosciences Gmbh Verfahren zum Nachweis, Differenzieren und Quantifizieren von T-Zellpopulationen mittels der Reverse Transkription quantitativen Real-Time PCR (RT-qPCR) Technologie
EP2606897A1 (en) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Methods and compositions for the treatment of diseases caused by enveloped viruses
CN102827826B (zh) * 2012-09-11 2017-07-04 赵永祥 一种诱导树突状细胞与肿瘤细胞融合的方法
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CN104830793A (zh) * 2015-05-05 2015-08-12 杨光华 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途
CA2985350A1 (en) * 2015-05-08 2016-11-17 Wilson Wolf Manufacturing Improved culture methods and devices for testing
WO2017004567A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
MX2018003757A (es) 2015-09-26 2018-09-21 Primevax Immuno Oncology Inc Composiciones y metodos para producir celulas dendriticas.
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030030A1 (en) * 1995-03-31 1996-10-03 Universite Libre De Bruxelles Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
WO1999037313A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Immune effector cell hybrids

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69839215T2 (de) * 1997-04-15 2009-03-19 Dana-Farber Cancer Institute, Inc., Boston Dendritische zellhybride

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996030030A1 (en) * 1995-03-31 1996-10-03 Universite Libre De Bruxelles Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
WO1999037313A1 (en) * 1998-01-26 1999-07-29 Genzyme Corporation Immune effector cell hybrids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CELLUZZI C M ET AL: "Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 160, no. 7, 1 April 1998 (1998-04-01), pages 3081 - 3085, XP002167051, ISSN: 0022-1767 *
CELLUZZI CHRISTINA M ET AL: "Immunization with dendritic cells fused with tumor cells elicits potent tumor specific immunity.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 108, no. 4, 1997, Annual Meeting of the Society for Investigative Dermatology;Washington, D.C., USA; April 23-27, 1997, pages 564, XP002919847, ISSN: 0022-202X *
GONG J ET AL: "INDUCTION OF ANTITUMOR ACTIVITY BY IMMUNIZATION WITH FUSIONS OF DENDRITIC AND CARCINOMA CELLS", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 3, no. 5, May 1997 (1997-05-01), pages 558 - 561, XP002910553, ISSN: 1078-8956 *
GONG J L ET AL: "FUSION OF HUMAN BREAST TUMOR AND DENDRITIC CELLS AS A NOVEL ANTITUMOR VACCINE", PROCEEDINGS OF THE 89TH. ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NEW ORLEANS, LA, MARCH 28 - APRIL 1, 1998, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA: AACR, US, vol. 39, March 1998 (1998-03-01), pages 172, XP002910557 *
See also references of WO0057705A1 *
WANG J ET AL: "Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 161, 1998, pages 5516 - 5524, XP002171426, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
EP1168924A1 (en) 2002-01-09
JP2002539805A (ja) 2002-11-26
WO2000057705A1 (en) 2000-10-05
AU4183100A (en) 2000-10-16
CN1353575A (zh) 2002-06-12
CA2367590A1 (en) 2000-10-05

Similar Documents

Publication Publication Date Title
EP1168924A4 (en) DERIVATIVED IMMUNOGENES IN VITRO INDUCTION OF ANTIQUE-SPECIFIC T-CELLS USING DENDRITIC CELL-TUMOR CELL OR DENDRITIC CELL-VIRAL CELL
FR2802799B1 (fr) Ensemble de prothese d'epaule
FI971955A0 (fi) Dopamineeristen solujen indusointi in vitro
IL144578A0 (en) Antibodies specific to kdr and uses thereof
EP1187626A4 (en) PROCESS FOR THE PREPARATION OF 5'-NUCLEIC ACID PROTEIN CONJUGATES
EP1150701A4 (en) TARGETING PRO-APOPTOTIC CONJUGATES AND METHODS FOR USE THEREOF
EP1303303A4 (en) ANTIGEN-BINDING POLYPEPTIDES FOR THE IMMUNOMODULATION OF THE HUMAN MHC CLASS II COMPLEX
EP1312670A4 (en) METHOD FOR THE EXTENSIVE CULTURE OF ANTIGEN-SPECIFIC CYTOTOXIC T CELLS
EP1189635A4 (en) AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY WITH T-CELLS OR B-CELLS B WHICH HAVE BEEN SENSITIZED TO ANTIGENS-SPECIFIC
GB9821193D0 (en) Mammalian artificial chromosomes and uses thereof
EP0939764A4 (en) MOLECULAR GENETIC CONSTRUCTION OF PASTEURELLACEAE-BASED VACCINE STRAINS
EP0775743A3 (en) Chicken cell liquid infected with Marek's disease virus
AU9374198A (en) Methods for producing human antibodies in scid mice using dendritic cells
AU2952202A (en) Immunogenic compositions comprising liver stage malarial antigens
EP1064947A4 (en) IN OVO VACCINATION AGAINST MAREK'S DISEASE VIRUS, TYPE 1
GB9916794D0 (en) In vitro virus reconstitution
IL129273A0 (en) Antibodies to placental protein 13
AUPQ257199A0 (en) Vaccine antigens of moraxella
FR2751519B3 (fr) Recipient de preparation d'eau chaude
AU697814B2 (en) Improvements in sustainable cell line for the production of Marek's disease vaccines
DE69938168D1 (de) Erysipelothrix rhusiopathiae Antigene und Impfstoff-Zusammensetzungen
AU8024100A (en) Induction of a strong immune response to a self-tumor associated antigen
EP1071325A4 (en) COMPOSITIONS AND METHODS FOR ANTI-SPECIFIC Vaccination
IL146777A0 (en) A method for the transfer of antigens to dendritic cells
GB9908628D0 (en) Electricity pylon

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011031

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020719

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 01N 63/00 A, 7C 12N 5/12 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021008